In this video, Berta Sousa, an oncologist at the Champalimaud Foundation’s Breast Unit and one of the people in charge of the BOUNCE project in Portugal, talks about the results already obtained concerning the factors that influence resilience to the diagnosis and treatments in breast cancer patients.  She also evokes a study of the impact of treatments on cognitive function, specifically performed by the Breast Unit, whose results will be presented shortly.

In this video, Radiation Oncologist Javier Morales, of the Champalimaud Foundation’s (CF) Breast Unit, describes state-of-the-art breast radiotherapy treatments and equipment in use at the CF, also referring to the multidisciplinarity and personalisation of patient care. 

In this video, Radiologist Celeste Alves, who leads the Breast Unit's Radiology Service at the Champalimaud Foundation, talks about the central role of breast radiology in the Unit’s activities, be they clinical services or research projects.

Cancer survival is estimated by cancer survival rates, which represent the percentage of people who survive a certain type of cancer for a specific amount of time. The most common are the five-year and 10-year survival rates.

Many of the most commonly diagnosed cancers have 10-year survival of 50% or more. More than 80% of people diagnosed with cancer types which are easier to diagnose and/or treat survive their cancer for ten years or more.

What distinguishes the Champalimaud Foundation’s Breast Unit from other units in the same field? In this short video, Fátima Cardoso, who leads the Breast Unit at the Champalimaud Foundation, answers this question.

October is World Breast Cancer Awareness Month. Fátima Cardoso, who leads the Breast Unit at the Champalimaud Foundation, presents here a series of short videos that will be published all through this month of October about the Breast Unit, its clinical activities and its research projects.

This public event, organised by the RAISE (Researchers in Action for Inclusion in Science and Education) consortium composed of the NGO Native Scientist, the Champalimaud Foundation and the Instituto de Medicina Molecular João Lobo Antunes (iMM), joined the 49 ERNs that took place in 25 European countries on the same date.

Two editions of the European Researchers’ Night will be held at the incredible premises of the Champalimaud Centre for the Unknown located in Lisbon.

To reach members of the public from underserved and underprivileged communities, the European Researchers’ Night will be supported by several pre-events and co-created by researchers and members of the public, namely students from the school programmes and artists.

Chemotherapy is the most conventional treatment against cancer. It uses medication to kill cells, and in particular cancer cells. But it does not target cancer cells specifically. It can be used by itself or in combination with other treatments, such as radiotherapy (see below) or surgery, to make them more effective.

Chemotherapy is usually administered intravenously at a hospital in the course of several sessions, but it can also consist of tablets taken at home. It can include one drug or a combination of drugs.

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.